Covariates in the model included patient age (with age 18-35 yeass as a reference group), gender, prescriber specialty, dummy variables for prior medication use, and medical and diagnostic histories.
On enrollment, the patient's age, sex, height, body weight, lifestyle, medical history, surgical history, prior medication, Helicobacter pylori infection status, history of the present illness, and QOL (measured using the QOLRAD-J) were recorded.
Each subject completed a standardized questionnaire about lifestyle factors, menstrual and reproductive history, past history of medical diseases, current and prior medication use, history of fractures, and family history of osteoporosis.
Patients with MDD receiving initial treatment with duloxetine were more likely to be older and to have comorbid medical conditions and complex prior medication treatment histories compared with their counterparts initially receiving venlafaxine XR.
A number of variables related to patient medical history (comorbidities, body system disorders, and prior medication use) were also identified by the logistic regression as affecting observed adherence rates.
During the screening period, information regarding the subject's medical history including but not limited to, prior medication and contraception use, alcohol consumption, and smoking history to assess those characteristics that may affect efficacy/safety or study variables, was recorded.
In general, age, preimplant INTERMACS profile, and prior medication use were associated with medication use at 3 months.Overall use of neurohormonal antagonists was low after LVAD implant, whereas use of loop diuretics and amiodarone remained high.
Prior medication use was generally similar across the treatment groups; however, the proportion of patients with prior respiratory system therapies was lower for the CC-930 100 mg BID group (29 %) compared with the placebo, CC-930 50 mg QD, and CC-930 100 mg QD dose groups (60, 63 and 88%%, respectively).
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression in the STAR*D study showed that remission rates with lithium and T(3) augmentation for participants who experienced unsatisfactory results with two prior medication treatments were modest and did not differ significantly (Nierenberg et al. 2006).
3. The assisted living facility said it was not responsible for reviewing medication lists from hospitals and then comparing them to prior medication lists.
However, we asked physicians to check each patient's file for all prior medication use.
